Insider · CIK 0002030561
Brad L. Tade
Files at ADMA (ADMA BIOLOGICS, INC.). First filing Nov 22, 2024, latest Nov 22, 2024.
In brief
Brad L. Tade files SEC Form 4 as CFO at ADMA (ADMA BIOLOGICS, INC.). Since Nov 22, 2024, Brad L. Tade has reported 0 open-market buys worth $0 and 1 open-market sell worth $317k, the latest filed on Nov 22, 2024.
A track record needs three past buys with six months of prices behind them; Brad L. Tade has 0, so none is measured yet.
The newest scored trade: sold $317k of ADMA on Nov 22, 2024, filed Nov 22, 2024, scored 44 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ADMA: ADMA BIOLOGICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | ADMA BIOLOGICS, INC. | $317k 15,000 shares | -7% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 10, 2026 | ADMA ADMA BIOLOGICS, INC. | 50,026 0.02% of outstanding | $791k | Mar 10, 2026 | none |
| Nov 22, 2024 | ADMA ADMA BIOLOGICS, INC. | 15,000 0.01% of outstanding | $320k | Nov 22, 2024 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | ADMA ADMA BIOLOGICS, INC. | FTax withholding Common Stock | -6,479 | $16.32 | $106k | 232,940 | Feb 23, 2026 |
| Jul 24, 2025 | ADMA ADMA BIOLOGICS, INC. | FTax withholding Common Stock | -7,123 | $17.31 | $123k | 239,419 | Jul 28, 2025 |
| Jun 26, 2025 | ADMA ADMA BIOLOGICS, INC. | FTax withholding Common Stock | -9,838 | $18.40 | $181k | 246,542 | Jun 30, 2025 |
| Feb 26, 2025 | ADMA ADMA BIOLOGICS, INC. | FTax withholding Common Stock | -5,280 | $15.78 | $83k | 256,380 | Feb 27, 2025 |
| Feb 19, 2025 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Common Stock | +62,227 | $0.00 | $0 | 261,660 | Feb 21, 2025 |
| Feb 19, 2025 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Stock Option (right to buy)derivative | +93,023 | $0.00 | $0 | 93,023 | Feb 21, 2025 |
| Nov 22, 2024 | ADMA ADMA BIOLOGICS, INC. | SOpen-market sale Common Stock | -15,000 | $21.15 | $317k | 199,433 | Nov 22, 2024 |
| Jul 24, 2024 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Common Stock | +72,400 | $0.00 | $0 | 214,433 | Jul 26, 2024 |
| Jul 24, 2024 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Stock Option (right to buy)derivative | +115,100 | $0.00 | $0 | 115,100 | Jul 26, 2024 |
Questions about Brad L. Tade
Answered from the filings on this page, as of the latest one.
Is Brad L. Tade buying or selling?
Not in the last 12 months. Brad L. Tade's latest open-market trade on SEC Form 4 was sold $317k of ADMA on Nov 22, 2024.
How did Brad L. Tade's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brad L. Tade has 0.
Where does Brad L. Tade file Form 4?
Brad L. Tade has filed Form 4 at ADMA (ADMA BIOLOGICS, INC.) as CFO and Treasurer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.